A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
NCT05628311 on ClinicalTrials.gov · last registry update 2024-08-20
Finished 25 October 2023, after enrolling 319 people. Primary outcome, as filed: HbA1c change from baseline at week 24. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 319
- Started
- 2023-01-06
- Primary completion
- 2023-10-25 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
HbA1c change from baseline at week 24
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.